Access BIO to support clinical advancement of disc stem cell program.
JUPITER, Fla., October 9, 2014--BioRestorative Therapies, Inc.(BRTX) has hired Access BIO, L.C. to provide strategic preclinical and regulatory consulting services related to the company's brtxDISC program.
Initially Access BIO will help the company prepare for pre-Investigational New Drug (IND) and TND meetings with the U.S. Food and Drug Administration (FDA).
brtxDISC (Disc Implanted Stem Cells) is an investigational non-surgical treatment for protruding and bulging lumbar.
The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
|Printer friendly Cite/link Email Feedback|
|Publication:||Stem Cell Lab World|
|Date:||Oct 20, 2014|
|Previous Article:||First patient treated in neuralstem phase 1 spinal cord injury stem cell trial.|
|Next Article:||Human stem cell patent challenge reaches Supreme Court.|